In an evidence-based review published in 2012, Laura Wakil, Samantha Meltzer-Brody, and Susan Girdler present a thorough review of premenstrual dysphoric disorder (PMDD), reviewing its diagnosis and treatment options.
There is excellent data to support the use of selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) for the treatment of premenstrual dysphoric disorder (PMDD); however, many women do not want to take [...]
Allopregnanolone is all over the place these days. We have seen several different allopregnanolone derivatives being used to treat postpartum depression (PPD). Last year, intravenous brexanolone (Zulresso) was approved by the FDA as the [...]
Not infrequently we see women who ask about the possibility of oophorectomy (surgical removal of the ovaries) as a means of managing what appears to be a menstrually related mood disorder. While this is an [...]
Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression. At that time, we were told that Zulresso would be available in June 2019. [...]
Chasteberry, the fruit of the chaste tree or Vitex agnus castus, has long been touted as a remedy for a range of reproductive problems, including premenstrual symptoms or PMS. Two recent publications have reviewed data [...]
